Scorpion Venom Could Help Treat Breast Cancer
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources.
Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content.
A venomous creature from the Amazon rainforest may hold the key to fighting one of the deadliest cancers affecting women today.
According to the American Cancer Society, skin cancers aside, breast cancer is the most common cancer among women in the U.S.—accounting for about 30% of all new female cancer cases annually, with an estimated 42,170 women expected to die from it in 2025.
Brazilian scientists have discovered that the venom of the Brotheas amazonicus scorpion contains a molecule that kills breast cancer cells in a way similar to chemotherapy, according to a groundbreaking study by researchers in Brazil.
"Through bioprospecting, we were able to identify a molecule in the species of this Amazonian scorpion that is similar to that found in the venoms of other scorpions and that acts against breast cancer cells," said Eliane Candiani Arantes, a professor at the University of São Paulo and the project's coordinator.
A stock image of a scorpion in the laboratory.
A stock image of a scorpion in the laboratory.
Sinhyu/iStock/Getty Images Plus
The molecule in question, called BamazScplp1, is a type of peptide—a short chain of amino acids—that showed cancer-fighting properties when tested in the lab.
It worka similarly to paclitaxel, a standard chemotherapy drug, by inducing necrosis, or uncontrolled cell death, in breast cancer cells.
Unlike some other cell-killing processes that are regulated by the body, necrosis causes the cancer cells to burst and die—a tactic that has also been observed in other venom-based compounds.
What Is Bioprospecting?
Bioprospecting is the process of searching for useful compounds in nature, especially from plants, animals, and microorganisms. In this case, the team explored scorpion venom for potential bioactive molecules—substances that affect living tissues in a beneficial way, such as fighting infections or cancer.
Turning Venom into Medicine—Without the Scorpions
The researchers aren't milking scorpions for their venom at scale. Instead, they are using a process called heterologous expression, which means inserting the gene that produces a particular protein into another organism—often yeast or bacteria—so it can be produced in large quantities in the lab.
"We also intend to obtain these molecules through heterologous expression," Arantes said, referring to BamazScplp1 and other promising compounds.
One such host organism is Pichia pastoris, a species of yeast originally isolated in France in 1950. It's commonly used in biotechnology to manufacture proteins that would otherwise be difficult to source naturally.
"Our idea now is to obtain this serine protease through heterologous expression [in a fragment or complete gene from a host organism that doesn't have it naturally] in Pichia pastoris," she added.
The "Super Glue" Made from Snake Venom
This isn't the first time researchers in Brazil have turned to venom for medical innovation. At the Center for the Study of Venoms and Venomous Animals (CEVAP), scientists developed a patented product called fibrin sealant—a kind of biological glue made by combining serinoproteinase (an enzyme found in snake venom) with cryoprecipitate, a component derived from the blood of buffalo, cattle, or sheep and is rich in fibrinogen, a protein essential for blood clotting.
When mixed, the two form a fibrin network, mimicking the body's natural healing process. This sealant has been studied for uses like nerve repair, bone injury treatment and even helping restore movement after spinal cord injuries. It is currently in phase three clinical trials, the last stage before a drug can be considered for approval and widespread use.
"This growth factor favors the formation of new vessels. If we combine it with colinein-1, we can create an improved fibrin sealant compared to the one being developed at CEVAP, with the possibility of expanding the industrial scale, since it can be obtained through heterologous expression," Arantes said.
A Bigger Push Toward Biopharmaceutical Innovation
All of this work is being carried out as part of the Center for Translational Science and Development of Biopharmaceuticals (CTS), a program aimed at turning biological discoveries into practical medical treatments. The CTS is part of a broader push by FAPESP, a public foundation in Brazil that funds scientific research.
Their strategy isn't limited to scorpion venom. The team has also worked with rattlesnake proteins, including a compound called cholinein-1, and is developing another bioactive substance known as CdtVEGF, which promotes the growth of blood vessels—a potentially valuable tool in tissue regeneration.
What Comes Next?
The discovery of BamazScplp1 is still in the early stages. The results were shared at FAPESP Week France, a scientific conference held from June 10 to 12 in Toulouse, southern France. But the findings highlight the growing interest in nature-based compounds and how they might work alongside or even replace traditional treatments like chemotherapy.
If further tests confirm its effectiveness and safety, the molecule from the scorpion could someday be developed into a new kind of anti-cancer drug, offering patients more options and possibly fewer side effects.
Do you have a tip on a health story that Newsweek should be covering? Do you have a question about breast cancer? Let us know via health@newsweek.com.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Newsweek
2 hours ago
- Newsweek
Cough Syrup Recall Sparks Nationwide Warning
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. Medtech Products Inc. is recalling the Little Remedies brand of Honey Cough Syrup due to fears the product may be contaminated with Bacillus cereus bacterium and concern over the product's shelf-life stability. Newsweek reached out to the company via email Wednesday for comment. Why It Matters Numerous recalls have been initiated in 2025 due to the potential of damaged products, foodborne illness, contamination and undeclared food allergens. Millions of Americans experience food sensitivities or allergies every year. According to the Food and Drug Administration (FDA), the nine "major" food allergens in the U.S. are eggs, milk, fish, wheat, soybeans, Crustacean shellfish, sesame, tree nuts and peanuts. The FDA also warns that people who consume products containing Bacillus cereus may experience nausea, vomiting or stomach cramps from one to six hours after consumption or eight to 16 hours later. "Although healthy individuals may suffer only short-term illness, exposure to high levels of foodborne B. cereus can cause death," the alert warns. What To Know In the alert, the FDA says the recalled product was distributed online and to nationwide retailers from December 14, 2022, to June 4, 2025. The alert has a chart showing UPC numbers with corresponding lot numbers and expiration dates for customers to reference. The recalled product was packaged in 4-fluid ounce bottles that are amber in color with an outside carton. Pictures of the recalled cough syrup are also in the FDA alert. The recall does not include other Little Remedies products, the agency says, adding that all lots of the Little Remedies Honey Cough 4-fluid ounce bottles "still within expiry are being included in the scope of the recall." There have been no "serious adverse events" related to the recall as of Wednesday, according to the FDA. What People Are Saying The FDA alert, in part: "Adverse reactions or quality problems experienced with the use of this product may be reported to the FDA's MedWatch Adverse Event Reporting program either online, by regular mail or by fax. Complete and submit the report Online: Regular Mail or Fax: Download form or call 1-800-332-1088 to request a reporting form, then complete and return to the address on the pre-addressed form, or submit by fax to 1-800-FDA-0178." What Happens Next Customers who have purchased the recalled cough syrup are advised to stop using the product and consult a medial professional if experiencing adverse reactions, the FDA says. Those with refund questions may contact the company via email at medicalaffairs@ by website at Link Disclaimer or via phone at (800) 754-8853 from 8:30 a.m. to 5:30 p.m. ET weekdays.
Newsweek
5 hours ago
- Newsweek
Scorpion Venom Could Help Treat Breast Cancer
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. A venomous creature from the Amazon rainforest may hold the key to fighting one of the deadliest cancers affecting women today. According to the American Cancer Society, skin cancers aside, breast cancer is the most common cancer among women in the U.S.—accounting for about 30% of all new female cancer cases annually, with an estimated 42,170 women expected to die from it in 2025. Brazilian scientists have discovered that the venom of the Brotheas amazonicus scorpion contains a molecule that kills breast cancer cells in a way similar to chemotherapy, according to a groundbreaking study by researchers in Brazil. "Through bioprospecting, we were able to identify a molecule in the species of this Amazonian scorpion that is similar to that found in the venoms of other scorpions and that acts against breast cancer cells," said Eliane Candiani Arantes, a professor at the University of São Paulo and the project's coordinator. A stock image of a scorpion in the laboratory. A stock image of a scorpion in the laboratory. Sinhyu/iStock/Getty Images Plus The molecule in question, called BamazScplp1, is a type of peptide—a short chain of amino acids—that showed cancer-fighting properties when tested in the lab. It worka similarly to paclitaxel, a standard chemotherapy drug, by inducing necrosis, or uncontrolled cell death, in breast cancer cells. Unlike some other cell-killing processes that are regulated by the body, necrosis causes the cancer cells to burst and die—a tactic that has also been observed in other venom-based compounds. What Is Bioprospecting? Bioprospecting is the process of searching for useful compounds in nature, especially from plants, animals, and microorganisms. In this case, the team explored scorpion venom for potential bioactive molecules—substances that affect living tissues in a beneficial way, such as fighting infections or cancer. Turning Venom into Medicine—Without the Scorpions The researchers aren't milking scorpions for their venom at scale. Instead, they are using a process called heterologous expression, which means inserting the gene that produces a particular protein into another organism—often yeast or bacteria—so it can be produced in large quantities in the lab. "We also intend to obtain these molecules through heterologous expression," Arantes said, referring to BamazScplp1 and other promising compounds. One such host organism is Pichia pastoris, a species of yeast originally isolated in France in 1950. It's commonly used in biotechnology to manufacture proteins that would otherwise be difficult to source naturally. "Our idea now is to obtain this serine protease through heterologous expression [in a fragment or complete gene from a host organism that doesn't have it naturally] in Pichia pastoris," she added. The "Super Glue" Made from Snake Venom This isn't the first time researchers in Brazil have turned to venom for medical innovation. At the Center for the Study of Venoms and Venomous Animals (CEVAP), scientists developed a patented product called fibrin sealant—a kind of biological glue made by combining serinoproteinase (an enzyme found in snake venom) with cryoprecipitate, a component derived from the blood of buffalo, cattle, or sheep and is rich in fibrinogen, a protein essential for blood clotting. When mixed, the two form a fibrin network, mimicking the body's natural healing process. This sealant has been studied for uses like nerve repair, bone injury treatment and even helping restore movement after spinal cord injuries. It is currently in phase three clinical trials, the last stage before a drug can be considered for approval and widespread use. "This growth factor favors the formation of new vessels. If we combine it with colinein-1, we can create an improved fibrin sealant compared to the one being developed at CEVAP, with the possibility of expanding the industrial scale, since it can be obtained through heterologous expression," Arantes said. A Bigger Push Toward Biopharmaceutical Innovation All of this work is being carried out as part of the Center for Translational Science and Development of Biopharmaceuticals (CTS), a program aimed at turning biological discoveries into practical medical treatments. The CTS is part of a broader push by FAPESP, a public foundation in Brazil that funds scientific research. Their strategy isn't limited to scorpion venom. The team has also worked with rattlesnake proteins, including a compound called cholinein-1, and is developing another bioactive substance known as CdtVEGF, which promotes the growth of blood vessels—a potentially valuable tool in tissue regeneration. What Comes Next? The discovery of BamazScplp1 is still in the early stages. The results were shared at FAPESP Week France, a scientific conference held from June 10 to 12 in Toulouse, southern France. But the findings highlight the growing interest in nature-based compounds and how they might work alongside or even replace traditional treatments like chemotherapy. If further tests confirm its effectiveness and safety, the molecule from the scorpion could someday be developed into a new kind of anti-cancer drug, offering patients more options and possibly fewer side effects. Do you have a tip on a health story that Newsweek should be covering? Do you have a question about breast cancer? Let us know via health@
Newsweek
7 hours ago
- Newsweek
Justice Sotomayor Says Supreme Court Just Countered 'Decades' of Precedent
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. Justice Sonia Sotomayor said the Supreme Court countered "decades" of legal precedent in its decision to uphold a Tennessee law banning certain medical treatments for transgender youth. The Court ruled 6-3 to uphold the legislation on Wednesday, with liberal Justices Sotomayor, Ketanji Brown Jackson and Elena Kagan dissenting. The Court's majority opinion, delivered by Chief Justice John Roberts, states that some medical treatments are "uniquely bound up in sex." "In the medical context, the mere use of sex-based language does not sweep a statute within the reach of heightened scrutiny," Roberts wrote. Sotomayor challenged this finding in her dissent. "Fashioning a medical-context-only exception also runs counter to decades of equal protection precedents," Sotomayor said. She added that the Court has previously held that "every sex-based distinction does warrant intermediate scrutiny." Supreme Court Justice Sonia Sotomayor speaks at an event in Miami, Florida, on February 11, 2025. Supreme Court Justice Sonia Sotomayor speaks at an event in Miami, Florida, on February 11, 2025. AP Photo/Lynne Sladky Why It Matters The legislation at the center of this case, Tennessee's Prohibition on Medical Procedures Performed on Minors Related to Sexual Identity, Senate Bill 1, was enacted in 2023. The law prohibits healthcare providers from prescribing, administering, or dispensing puberty blockers or hormones to minors. Three transgender minors, their parents and a doctor challenged the law. The Supreme Court's ruling comes amid debates over the rights of transgender individuals under the law at both the state and federal levels. President Donald Trump signed an executive order on January 20, declaring that sex is "not changeable" and shall refer to an individual's biological classification as male or female. What To Know Roberts called the plaintiff's allegations of stereotyping on the basis of sex "misplaced." "SB1 does not exclude any individual from medical treatments on the basis of transgender status but rather removes one set of diagnoses—gender dysphoria, gender identity disorder, and gender incongruence—from the range of treatable conditions," Roberts said. Sotomayor said sex determines who has access to the medications restricted under Tennessee's law. "Yet the majority refuses to call a spade a spade," Sotomayor said. "Instead, it obfuscates a sex classification that is plain on the face of this statute, all to avoid the mere possibility that a different court could strike down SB1, or categorical healthcare bans like it." The decision was met with criticism from legal rights and advocacy groups, including the Human Rights Campaign. The group's president, Kelley Robinson, called the ruling a "devastating blow to transgender youth and the families who love them" in a statement sent to Newsweek. "This Court chose to allow politicians to interfere in medical decisions that should be made by doctors, patients, and families—a cruel betrayal of the children who needed them to stand up for justice when it mattered most," Robinson said. What People Are Saying Supreme Court Justice Sonia Sotomayor, in a dissent: "The Court's willingness to do so here does irrevocable damage to the Equal Protection Clause and invites legislatures to engage in discrimination by hiding blatant sex classifications in plain sight. It also authorizes, without second thought, untold harm to transgender children and the parents and families who love them. Because there is no constitutional justification for that result, I dissent." Supreme Court Chief Justice John Roberts, in the Court's majority opinion: "This case carries with it the weight of fierce scientific and policy debates about the safety, efficacy, and propriety of medical treatments in an evolving field. The voices in these debates raise sincere concerns; the implications for all are profound. The Equal Protection Clause does not resolve these disagreements. Nor does it afford us license to decide them as we see best." Human Rights Campaign President Kelley Robinson, in a statement sent to Newsweek: "As parents, advocates, and community leaders, we know that our fight doesn't end in courtrooms—it lives in our communities, our hearts, and our unwavering commitment to each other. Still, we will not be deterred." GLAD Law Senior Director of Transgender and Queer Rights Jennifer Levi told Newsweek: "The Court today failed to do its job. When the political system breaks down and legislatures bow to popular hostility, the judiciary must be the Constitution's backbone. Instead, it chose to look away, abandoning both vulnerable children and the parents who love them. No parent should be forced to watch their child suffer while proven medical care sits beyond their reach because of politics." What Happens Next The Court's ruling affirmed the decision made by the Sixth Circuit Court of Appeals. The decision upholds Tennessee's law banning puberty blockers and hormones among minors. Do you have a story that Newsweek should be covering? Do you have any questions about this story? Contact LiveNews@
